

Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis

NCT06836557

Status	RECRUITING
Phase	Phase 3
Sponsor	Vanda Pharmaceuticals
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (4)

- Diagnosed with gastroparesis
- Demonstrated delayed gastric emptying
- Presence of moderate to severe nausea
- Body Mass Index (BMI) of ≥ 18 and ≤ 40 kg/m²

Exclusion (4)

- Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis
- A positive test for drugs of abuse at the screening or evaluation visits
- Pregnancy or nursing
- Evidence of uncontrolled blood glucose (including HbA1C $\geq 11\%$ at screening or metabolic crisis in past 60 days)

Locations (3 total)

Vanda Investigational Site, Leuven, Belgium
Vanda Investigational Site, Liège, Belgium
Vanda Investigational Site, Leipzig, Germany